Susan E. Siegel
Known title: DirectorCIK: 0001240363
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Align Technology Sets Q3 2026 Earnings Date for October 28. Align Technology has scheduled its third-quarter 2026 earnings release for October 28, 2026. This announcement comes as the stock trades near its 52-week low, prompting market discussions about whether the current valuation is reasonable after a significant decline. Analysts continue to watch the company's position in the dental equipment sector, with average price targets remaining above current levels.
Transaction History
| ILMN | ▲ Buy | Grant | 2,072 | $300K | 5/21/2026 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,745 | $0 | 5/20/2026 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,148 | $0 | 5/21/2025 | View on chart |
| ILMN | ▲ Buy | Grant | 3,780 | $0 | 5/21/2025 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,029 | $0 | 5/17/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 2,622 | $0 | 5/16/2024 | View on chart |
| ILMN | ▲ Buy | Grant | 1,532 | $0 | 5/26/2023 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 1,114 | $0 | 5/17/2023 | View on chart |
| ILMN | ▲ Buy | Grant | 1,232 | $0 | 5/26/2022 | View on chart |
| ILMN | ▼ Sell | Tax Withholding | 352 | $85K | 5/25/2022 | View on chart |
| ALGN | ▲ Buy | Option Exercise | 524 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends
Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.
Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.